Debopam Samanta
Concepts (324)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Epilepsy | 27 | 2024 | 174 | 13.030 |
Why?
| Seizures | 21 | 2024 | 195 | 4.930 |
Why?
| Spasms, Infantile | 9 | 2024 | 27 | 4.070 |
Why?
| Anticonvulsants | 12 | 2023 | 121 | 3.850 |
Why?
| Cannabidiol | 5 | 2022 | 37 | 3.640 |
Why?
| Status Epilepticus | 6 | 2021 | 39 | 3.530 |
Why?
| Tuberous Sclerosis | 6 | 2022 | 37 | 3.480 |
Why?
| Mutation | 16 | 2023 | 1294 | 3.250 |
Why?
| Electroencephalography | 17 | 2022 | 306 | 2.470 |
Why?
| Humans | 103 | 2024 | 49974 | 2.440 |
Why?
| Epilepsies, Myoclonic | 4 | 2020 | 11 | 2.360 |
Why?
| Intellectual Disability | 5 | 2023 | 125 | 2.320 |
Why?
| Hemiplegia | 3 | 2021 | 11 | 2.150 |
Why?
| Brain | 9 | 2019 | 1328 | 2.130 |
Why?
| Child | 37 | 2024 | 6847 | 2.080 |
Why?
| Developmental Disabilities | 5 | 2019 | 119 | 1.800 |
Why?
| Epilepsy, Absence | 3 | 2019 | 11 | 1.750 |
Why?
| Magnetic Resonance Imaging | 15 | 2019 | 1537 | 1.670 |
Why?
| Tumor Suppressor Proteins | 3 | 2023 | 128 | 1.500 |
Why?
| Neuroaxonal Dystrophies | 2 | 2022 | 8 | 1.490 |
Why?
| Nervous System Malformations | 3 | 2020 | 17 | 1.480 |
Why?
| Folate Receptor 1 | 2 | 2022 | 24 | 1.460 |
Why?
| Epilepsies, Partial | 2 | 2022 | 11 | 1.370 |
Why?
| Infant, Newborn, Diseases | 2 | 2020 | 57 | 1.360 |
Why?
| Ketamine | 2 | 2020 | 60 | 1.350 |
Why?
| Infant | 18 | 2024 | 3567 | 1.280 |
Why?
| Neurocutaneous Syndromes | 2 | 2019 | 6 | 1.230 |
Why?
| Child, Preschool | 19 | 2024 | 3871 | 1.210 |
Why?
| Cadherins | 2 | 2019 | 68 | 1.200 |
Why?
| Deep Brain Stimulation | 2 | 2024 | 40 | 1.150 |
Why?
| Cerebral Arteries | 2 | 2019 | 40 | 1.120 |
Why?
| Epilepsy, Generalized | 2 | 2023 | 8 | 1.110 |
Why?
| Sirolimus | 2 | 2017 | 62 | 1.090 |
Why?
| Angiofibroma | 2 | 2015 | 5 | 1.050 |
Why?
| Facial Neoplasms | 2 | 2015 | 22 | 1.030 |
Why?
| Nerve Tissue Proteins | 2 | 2018 | 193 | 1.020 |
Why?
| Valproic Acid | 2 | 2022 | 32 | 1.010 |
Why?
| Stroke | 3 | 2019 | 492 | 0.960 |
Why?
| Thalamus | 1 | 2024 | 36 | 0.950 |
Why?
| Male | 33 | 2024 | 25241 | 0.930 |
Why?
| Pregnanolone | 2 | 2023 | 6 | 0.920 |
Why?
| Female | 29 | 2024 | 26472 | 0.910 |
Why?
| Landau-Kleffner Syndrome | 1 | 2022 | 3 | 0.870 |
Why?
| Treatment Outcome | 10 | 2024 | 5141 | 0.840 |
Why?
| Quality Improvement | 2 | 2022 | 208 | 0.840 |
Why?
| Aphasia | 1 | 2022 | 31 | 0.830 |
Why?
| Nervous System Diseases | 2 | 2021 | 88 | 0.810 |
Why?
| Chromosome Deletion | 3 | 2019 | 140 | 0.790 |
Why?
| Abnormalities, Multiple | 3 | 2023 | 167 | 0.790 |
Why?
| Emergencies | 1 | 2021 | 86 | 0.760 |
Why?
| Pharmaceutical Preparations | 1 | 2021 | 77 | 0.750 |
Why?
| Angelman Syndrome | 1 | 2020 | 1 | 0.750 |
Why?
| Transition to Adult Care | 1 | 2020 | 17 | 0.740 |
Why?
| Immunoglobulins, Intravenous | 1 | 2021 | 54 | 0.730 |
Why?
| Bone Diseases, Developmental | 2 | 2023 | 14 | 0.720 |
Why?
| Tooth Abnormalities | 2 | 2023 | 12 | 0.720 |
Why?
| Fenfluramine | 1 | 2020 | 7 | 0.720 |
Why?
| Oligonucleotides, Antisense | 1 | 2020 | 28 | 0.710 |
Why?
| Phenobarbital | 1 | 2020 | 17 | 0.710 |
Why?
| Dioxolanes | 1 | 2020 | 12 | 0.710 |
Why?
| Behavioral Symptoms | 1 | 2019 | 2 | 0.700 |
Why?
| Flunarizine | 1 | 2019 | 1 | 0.700 |
Why?
| Immunologic Factors | 1 | 2021 | 114 | 0.700 |
Why?
| Excitatory Amino Acid Antagonists | 1 | 2020 | 51 | 0.700 |
Why?
| Ocular Physiological Phenomena | 1 | 2019 | 4 | 0.690 |
Why?
| Tetrasomy | 1 | 2019 | 2 | 0.690 |
Why?
| Agenesis of Corpus Callosum | 2 | 2018 | 10 | 0.680 |
Why?
| Chromosomes, Human, Pair 5 | 1 | 2019 | 17 | 0.680 |
Why?
| Sneddon Syndrome | 1 | 2019 | 3 | 0.680 |
Why?
| Livedo Reticularis | 1 | 2019 | 5 | 0.680 |
Why?
| Oral Ulcer | 1 | 2019 | 3 | 0.680 |
Why?
| Behcet Syndrome | 1 | 2019 | 7 | 0.670 |
Why?
| Calcium Channel Blockers | 1 | 2019 | 62 | 0.670 |
Why?
| Transposases | 1 | 2019 | 10 | 0.670 |
Why?
| Andersen Syndrome | 1 | 2019 | 1 | 0.670 |
Why?
| Genetic Therapy | 1 | 2020 | 114 | 0.660 |
Why?
| Hydrocephalus | 1 | 2019 | 42 | 0.660 |
Why?
| Spinal Cord Diseases | 1 | 2019 | 37 | 0.660 |
Why?
| Receptors, GABA-B | 1 | 2019 | 11 | 0.660 |
Why?
| Vitiligo | 1 | 2019 | 8 | 0.660 |
Why?
| Nephrotic Syndrome | 2 | 2017 | 17 | 0.660 |
Why?
| Leukoencephalopathies | 1 | 2019 | 14 | 0.660 |
Why?
| Autoimmune Diseases of the Nervous System | 1 | 2019 | 9 | 0.660 |
Why?
| Cytochrome-c Oxidase Deficiency | 1 | 2018 | 3 | 0.650 |
Why?
| Migraine Disorders | 2 | 2020 | 47 | 0.650 |
Why?
| Edema | 1 | 2019 | 67 | 0.650 |
Why?
| Electron Transport Complex IV | 1 | 2018 | 25 | 0.650 |
Why?
| Cannabinoid Receptor Agonists | 1 | 2019 | 49 | 0.650 |
Why?
| Cerebral Infarction | 1 | 2018 | 39 | 0.640 |
Why?
| Muscle Weakness | 1 | 2019 | 44 | 0.640 |
Why?
| Diffuse Cerebral Sclerosis of Schilder | 1 | 2018 | 8 | 0.640 |
Why?
| Amino Acyl-tRNA Synthetases | 1 | 2018 | 6 | 0.640 |
Why?
| Shab Potassium Channels | 1 | 2018 | 2 | 0.640 |
Why?
| Optic Atrophy | 1 | 2018 | 17 | 0.640 |
Why?
| Physicians | 1 | 2022 | 233 | 0.640 |
Why?
| Photic Stimulation | 1 | 2018 | 60 | 0.640 |
Why?
| Alopecia | 1 | 2019 | 39 | 0.630 |
Why?
| Parents | 1 | 2021 | 314 | 0.630 |
Why?
| Brain Edema | 1 | 2018 | 41 | 0.630 |
Why?
| Lymphohistiocytosis, Hemophagocytic | 1 | 2018 | 26 | 0.620 |
Why?
| Thrombocytopenia | 1 | 2019 | 85 | 0.620 |
Why?
| Myoclonus | 1 | 2018 | 9 | 0.620 |
Why?
| Artifacts | 1 | 2018 | 53 | 0.610 |
Why?
| Biomedical Research | 1 | 2021 | 237 | 0.610 |
Why?
| Mitochondrial Diseases | 1 | 2018 | 42 | 0.610 |
Why?
| Autoimmune Diseases | 1 | 2019 | 101 | 0.610 |
Why?
| Practice Guidelines as Topic | 1 | 2020 | 449 | 0.600 |
Why?
| Neurodegenerative Diseases | 1 | 2018 | 76 | 0.600 |
Why?
| Hearing Loss, Sensorineural | 1 | 2018 | 75 | 0.580 |
Why?
| Osteochondrodysplasias | 1 | 2017 | 13 | 0.580 |
Why?
| Immunologic Deficiency Syndromes | 1 | 2017 | 20 | 0.580 |
Why?
| Adolescent | 13 | 2024 | 6356 | 0.580 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 488 | 0.570 |
Why?
| Arteriosclerosis | 1 | 2017 | 54 | 0.570 |
Why?
| Phenotype | 2 | 2021 | 729 | 0.570 |
Why?
| Carotid Artery Diseases | 1 | 2017 | 33 | 0.570 |
Why?
| Models, Biological | 1 | 2020 | 727 | 0.570 |
Why?
| Infant, Newborn | 6 | 2024 | 2772 | 0.570 |
Why?
| Drug Discovery | 1 | 2017 | 85 | 0.560 |
Why?
| Child Development | 1 | 2018 | 190 | 0.560 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2018 | 186 | 0.550 |
Why?
| Cafe-au-Lait Spots | 1 | 2016 | 2 | 0.550 |
Why?
| Erythema Infectiosum | 1 | 2015 | 3 | 0.540 |
Why?
| Migraine with Aura | 1 | 2015 | 4 | 0.540 |
Why?
| Skin | 1 | 2019 | 409 | 0.540 |
Why?
| Leukoencephalitis, Acute Hemorrhagic | 1 | 2015 | 3 | 0.540 |
Why?
| Williams Syndrome | 1 | 2016 | 27 | 0.530 |
Why?
| Corpus Callosum | 2 | 2023 | 28 | 0.530 |
Why?
| Sinus Pericranii | 1 | 2015 | 1 | 0.530 |
Why?
| Syndrome | 6 | 2024 | 237 | 0.530 |
Why?
| Parvovirus B19, Human | 1 | 2015 | 17 | 0.530 |
Why?
| Pulmonary Embolism | 1 | 2017 | 97 | 0.530 |
Why?
| Toes | 1 | 2015 | 15 | 0.530 |
Why?
| SOS1 Protein | 1 | 2015 | 2 | 0.530 |
Why?
| Electrodiagnosis | 1 | 2015 | 12 | 0.530 |
Why?
| Crying | 1 | 2015 | 4 | 0.530 |
Why?
| Moyamoya Disease | 1 | 2015 | 7 | 0.520 |
Why?
| Hyperventilation | 1 | 2015 | 8 | 0.520 |
Why?
| Tuberculoma | 1 | 2015 | 2 | 0.520 |
Why?
| Iatrogenic Disease | 1 | 2015 | 24 | 0.520 |
Why?
| Epilepsy, Benign Neonatal | 1 | 2015 | 2 | 0.520 |
Why?
| Noonan Syndrome | 1 | 2015 | 12 | 0.520 |
Why?
| Neurologic Examination | 1 | 2015 | 77 | 0.520 |
Why?
| Encephalitis | 1 | 2016 | 41 | 0.520 |
Why?
| Mutism | 1 | 2015 | 3 | 0.510 |
Why?
| NAV1.2 Voltage-Gated Sodium Channel | 1 | 2015 | 3 | 0.510 |
Why?
| Communication | 3 | 2022 | 246 | 0.510 |
Why?
| Ocular Motility Disorders | 1 | 2015 | 17 | 0.510 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2015 | 77 | 0.500 |
Why?
| Repressor Proteins | 2 | 2023 | 151 | 0.500 |
Why?
| Diagnosis, Differential | 7 | 2020 | 1037 | 0.500 |
Why?
| Trisomy | 1 | 2014 | 31 | 0.500 |
Why?
| Influenza, Human | 1 | 2015 | 84 | 0.490 |
Why?
| KCNQ2 Potassium Channel | 1 | 2014 | 9 | 0.480 |
Why?
| Energy Drinks | 1 | 2014 | 6 | 0.480 |
Why?
| Neurology | 1 | 2015 | 41 | 0.480 |
Why?
| Vasoconstriction | 1 | 2014 | 54 | 0.480 |
Why?
| Benzodiazepines | 1 | 2014 | 70 | 0.470 |
Why?
| Osteomyelitis | 1 | 2015 | 126 | 0.470 |
Why?
| Membrane Proteins | 1 | 2016 | 341 | 0.460 |
Why?
| Sleep | 1 | 2014 | 184 | 0.450 |
Why?
| Enzyme Inhibitors | 1 | 2015 | 391 | 0.440 |
Why?
| Magnetic Resonance Angiography | 3 | 2019 | 77 | 0.420 |
Why?
| Immunosuppressive Agents | 3 | 2019 | 221 | 0.410 |
Why?
| Pediatrics | 1 | 2015 | 279 | 0.400 |
Why?
| Quality of Life | 3 | 2022 | 836 | 0.380 |
Why?
| Diffusion Magnetic Resonance Imaging | 3 | 2017 | 123 | 0.360 |
Why?
| Receptors, N-Methyl-D-Aspartate | 2 | 2022 | 127 | 0.360 |
Why?
| Caregivers | 2 | 2021 | 208 | 0.340 |
Why?
| Recurrence | 3 | 2019 | 652 | 0.330 |
Why?
| Echinocandins | 1 | 2008 | 64 | 0.320 |
Why?
| Mycoses | 1 | 2008 | 157 | 0.290 |
Why?
| Gastroesophageal Reflux | 2 | 2019 | 49 | 0.290 |
Why?
| Antifungal Agents | 1 | 2008 | 339 | 0.260 |
Why?
| Administration, Topical | 2 | 2015 | 56 | 0.260 |
Why?
| Retrospective Studies | 6 | 2023 | 6108 | 0.260 |
Why?
| Adult | 5 | 2024 | 13236 | 0.240 |
Why?
| Intralaminar Thalamic Nuclei | 1 | 2024 | 6 | 0.240 |
Why?
| Databases, Factual | 2 | 2024 | 658 | 0.230 |
Why?
| Psychosurgery | 1 | 2023 | 5 | 0.230 |
Why?
| Laser Therapy | 1 | 2023 | 84 | 0.220 |
Why?
| Speech Disorders | 1 | 2022 | 16 | 0.220 |
Why?
| Ethosuximide | 1 | 2022 | 5 | 0.210 |
Why?
| Clonazepam | 1 | 2022 | 5 | 0.210 |
Why?
| Electrodes, Implanted | 1 | 2022 | 30 | 0.210 |
Why?
| Stereotaxic Techniques | 1 | 2022 | 37 | 0.210 |
Why?
| Cluster Analysis | 1 | 2023 | 235 | 0.210 |
Why?
| Death, Sudden | 1 | 2022 | 10 | 0.210 |
Why?
| GTPase-Activating Proteins | 1 | 2022 | 23 | 0.210 |
Why?
| Review Literature as Topic | 1 | 2022 | 18 | 0.210 |
Why?
| Palliative Care | 1 | 2024 | 187 | 0.200 |
Why?
| Concept Formation | 1 | 2021 | 12 | 0.200 |
Why?
| Perivascular Epithelioid Cell Neoplasms | 1 | 2021 | 4 | 0.200 |
Why?
| Freedom | 1 | 2021 | 3 | 0.200 |
Why?
| Folic Acid | 1 | 2022 | 135 | 0.200 |
Why?
| Diazepam | 1 | 2021 | 17 | 0.200 |
Why?
| Drug Interactions | 1 | 2022 | 206 | 0.190 |
Why?
| Fibroma | 1 | 2021 | 39 | 0.190 |
Why?
| Risk Factors | 2 | 2020 | 3613 | 0.190 |
Why?
| Adrenocorticotropic Hormone | 2 | 2022 | 31 | 0.190 |
Why?
| Personal Satisfaction | 1 | 2021 | 75 | 0.190 |
Why?
| Soft Tissue Neoplasms | 1 | 2021 | 57 | 0.190 |
Why?
| Brain Diseases | 1 | 2021 | 82 | 0.190 |
Why?
| Dihydroergotamine | 1 | 2020 | 4 | 0.190 |
Why?
| Perception | 1 | 2021 | 116 | 0.180 |
Why?
| Facies | 2 | 2023 | 35 | 0.180 |
Why?
| Transcription Factors | 2 | 2023 | 561 | 0.180 |
Why?
| Diet Therapy | 1 | 2020 | 8 | 0.180 |
Why?
| Genetic Diseases, Inborn | 1 | 2020 | 24 | 0.180 |
Why?
| Consensus | 1 | 2021 | 148 | 0.180 |
Why?
| Clinical Protocols | 1 | 2020 | 108 | 0.180 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2020 | 92 | 0.180 |
Why?
| Treatment Failure | 1 | 2020 | 114 | 0.170 |
Why?
| Anesthetics | 1 | 2020 | 36 | 0.170 |
Why?
| Leukomalacia, Periventricular | 1 | 2019 | 12 | 0.170 |
Why?
| Muscle Hypotonia | 1 | 2019 | 21 | 0.170 |
Why?
| Qualitative Research | 1 | 2021 | 329 | 0.170 |
Why?
| Chromosomes, Human, Pair 7 | 1 | 2019 | 29 | 0.170 |
Why?
| Matrix Attachment Region Binding Proteins | 1 | 2020 | 34 | 0.170 |
Why?
| HLA-B51 Antigen | 1 | 2019 | 2 | 0.170 |
Why?
| Learning | 1 | 2021 | 158 | 0.170 |
Why?
| Patient-Centered Care | 1 | 2021 | 129 | 0.170 |
Why?
| Craniofacial Abnormalities | 1 | 2019 | 26 | 0.170 |
Why?
| Ventriculoperitoneal Shunt | 1 | 2019 | 26 | 0.170 |
Why?
| Analgesics, Non-Narcotic | 1 | 2020 | 117 | 0.170 |
Why?
| Heart Septal Defects, Atrial | 1 | 2019 | 44 | 0.170 |
Why?
| Potassium Channels, Inwardly Rectifying | 1 | 2019 | 7 | 0.170 |
Why?
| Ventricular Premature Complexes | 1 | 2019 | 7 | 0.170 |
Why?
| Disease Management | 1 | 2020 | 174 | 0.170 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2022 | 549 | 0.170 |
Why?
| Microcephaly | 1 | 2019 | 41 | 0.160 |
Why?
| Melkersson-Rosenthal Syndrome | 1 | 2018 | 4 | 0.160 |
Why?
| Facial Nerve Diseases | 1 | 2018 | 6 | 0.160 |
Why?
| Referral and Consultation | 1 | 2021 | 285 | 0.160 |
Why?
| Syncope | 1 | 2019 | 28 | 0.160 |
Why?
| Nocturnal Myoclonus Syndrome | 1 | 2018 | 13 | 0.160 |
Why?
| Cerebral Veins | 1 | 2018 | 15 | 0.160 |
Why?
| Facial Paralysis | 1 | 2018 | 24 | 0.160 |
Why?
| Anti-Arrhythmia Agents | 1 | 2019 | 79 | 0.160 |
Why?
| Health Personnel | 1 | 2021 | 246 | 0.160 |
Why?
| Deglutition Disorders | 1 | 2019 | 77 | 0.160 |
Why?
| Acute Disease | 1 | 2019 | 366 | 0.160 |
Why?
| Fatal Outcome | 1 | 2019 | 195 | 0.160 |
Why?
| Video Recording | 1 | 2018 | 79 | 0.160 |
Why?
| Frameshift Mutation | 1 | 2018 | 17 | 0.160 |
Why?
| Fibrinolytic Agents | 1 | 2019 | 124 | 0.150 |
Why?
| Clinical Trials as Topic | 1 | 2020 | 461 | 0.150 |
Why?
| Combined Modality Therapy | 1 | 2020 | 637 | 0.150 |
Why?
| Anti-Inflammatory Agents | 1 | 2019 | 161 | 0.150 |
Why?
| Fear | 1 | 2018 | 82 | 0.150 |
Why?
| India | 1 | 2017 | 51 | 0.150 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2019 | 172 | 0.150 |
Why?
| History, 21st Century | 1 | 2017 | 56 | 0.150 |
Why?
| Cerebellum | 1 | 2018 | 135 | 0.150 |
Why?
| History, 20th Century | 1 | 2017 | 99 | 0.150 |
Why?
| Methotrexate | 1 | 2017 | 69 | 0.150 |
Why?
| Neurotoxicity Syndromes | 1 | 2017 | 46 | 0.150 |
Why?
| Anti-Infective Agents | 1 | 2017 | 95 | 0.140 |
Why?
| Pandemics | 1 | 2021 | 559 | 0.140 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 92 | 0.140 |
Why?
| Animals | 3 | 2022 | 13187 | 0.140 |
Why?
| Aldehyde Dehydrogenase | 1 | 2016 | 26 | 0.140 |
Why?
| Hormones | 1 | 2016 | 55 | 0.130 |
Why?
| Influenza B virus | 1 | 2015 | 6 | 0.130 |
Why?
| Delayed Diagnosis | 1 | 2016 | 23 | 0.130 |
Why?
| Chromosomes, Human, Pair 3 | 1 | 2015 | 19 | 0.130 |
Why?
| Arkansas | 1 | 2021 | 1977 | 0.130 |
Why?
| North America | 1 | 2015 | 64 | 0.130 |
Why?
| Cerebral Angiography | 1 | 2015 | 97 | 0.130 |
Why?
| Antibiotics, Antineoplastic | 1 | 2015 | 78 | 0.120 |
Why?
| Chromosomes, Human, Pair 9 | 1 | 2014 | 19 | 0.120 |
Why?
| Complementary Therapies | 1 | 2015 | 25 | 0.120 |
Why?
| Brain Waves | 1 | 2014 | 18 | 0.120 |
Why?
| Drug Resistance | 1 | 2015 | 63 | 0.120 |
Why?
| Antiemetics | 1 | 2014 | 32 | 0.120 |
Why?
| Polymerase Chain Reaction | 1 | 2015 | 453 | 0.120 |
Why?
| Headache | 1 | 2014 | 76 | 0.120 |
Why?
| Vomiting | 1 | 2014 | 75 | 0.120 |
Why?
| Glutamine | 1 | 2015 | 171 | 0.120 |
Why?
| Mutation, Missense | 1 | 2014 | 105 | 0.110 |
Why?
| Arginine | 1 | 2015 | 179 | 0.110 |
Why?
| Analgesics | 1 | 2014 | 100 | 0.110 |
Why?
| Decision Making, Computer-Assisted | 1 | 2013 | 4 | 0.110 |
Why?
| Diagnostic Errors | 1 | 2013 | 63 | 0.110 |
Why?
| Vigabatrin | 2 | 2022 | 2 | 0.110 |
Why?
| Evidence-Based Medicine | 1 | 2013 | 247 | 0.100 |
Why?
| Inflammation | 1 | 2016 | 604 | 0.100 |
Why?
| Pregnancy | 1 | 2018 | 2607 | 0.090 |
Why?
| Signal Transduction | 1 | 2017 | 1618 | 0.090 |
Why?
| Dysentery | 1 | 2009 | 1 | 0.080 |
Why?
| Trichuriasis | 1 | 2009 | 1 | 0.080 |
Why?
| Trichuris | 1 | 2009 | 1 | 0.080 |
Why?
| Antineoplastic Agents | 1 | 2017 | 1171 | 0.080 |
Why?
| Anesthesia, Intravenous | 1 | 2008 | 13 | 0.080 |
Why?
| Eosinophils | 1 | 2009 | 39 | 0.080 |
Why?
| Lipopeptides | 1 | 2008 | 63 | 0.080 |
Why?
| Amyloidosis | 1 | 2009 | 79 | 0.080 |
Why?
| Inflammatory Bowel Diseases | 1 | 2009 | 53 | 0.080 |
Why?
| Tuberculosis | 1 | 2009 | 146 | 0.080 |
Why?
| Candidiasis | 1 | 2008 | 114 | 0.080 |
Why?
| Aspergillosis | 1 | 2008 | 125 | 0.070 |
Why?
| Kidney Diseases | 1 | 2009 | 214 | 0.070 |
Why?
| Prospective Studies | 2 | 2023 | 2364 | 0.070 |
Why?
| Spasm | 1 | 2024 | 9 | 0.060 |
Why?
| Feedback | 1 | 2024 | 52 | 0.060 |
Why?
| Probability | 1 | 2023 | 164 | 0.060 |
Why?
| Neuroimaging | 1 | 2023 | 84 | 0.050 |
Why?
| Neurosurgical Procedures | 1 | 2024 | 121 | 0.050 |
Why?
| Potassium Channels | 1 | 2021 | 31 | 0.050 |
Why?
| Registries | 1 | 2024 | 522 | 0.050 |
Why?
| Administration, Intravenous | 1 | 2020 | 69 | 0.050 |
Why?
| Sleep Stages | 1 | 2020 | 45 | 0.040 |
Why?
| Age of Onset | 1 | 2020 | 108 | 0.040 |
Why?
| Cognition | 1 | 2022 | 338 | 0.040 |
Why?
| Immunohistochemistry | 1 | 2021 | 973 | 0.040 |
Why?
| Software | 1 | 2013 | 273 | 0.020 |
Why?
| Internet | 1 | 2013 | 259 | 0.020 |
Why?
| Young Adult | 1 | 2020 | 3958 | 0.020 |
Why?
| Mebendazole | 1 | 2009 | 2 | 0.020 |
Why?
| Antinematodal Agents | 1 | 2009 | 3 | 0.020 |
Why?
| Leukemoid Reaction | 1 | 2009 | 6 | 0.020 |
Why?
| Antitubercular Agents | 1 | 2009 | 106 | 0.020 |
Why?
| Colonoscopy | 1 | 2009 | 93 | 0.020 |
Why?
| Prognosis | 1 | 2009 | 1942 | 0.010 |
Why?
|
|
Samanta's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|